Sorrento Therapeutics, Inc.: COVID-19 trials
The registry lists 18 COVID-19 studies with Sorrento Therapeutics, Inc. as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 5Phase 2 15(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19CompletedNCT04440007Phase 2Results posted
- Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and AdolescentsWithdrawnNCT05372783Phase 2
- Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy VolunteersCompletedNCT05364840Phase 1
- Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 InfectionWithdrawnNCT05074394Phase 2
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromiseWithdrawnNCT04992247Phase 2
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromiseWithdrawnNCT04909892Phase 2
- Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)CompletedNCT04906694Phase 2
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory DistressStatus unknownNCT04905836Phase 2
- Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory DistressTerminatedNCT04903327Phase 2
- Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)TerminatedNCT04900428Phase 2
- Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19WithdrawnNCT04771351Phase 2
- Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19WithdrawnNCT04738175Phase 1/2
- Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 SymptomsWithdrawnNCT04734860Phase 2
- Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory DistressWithdrawnNCT04728698Phase 2
- Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19WithdrawnNCT04584697Phase 1/2
- Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19CompletedNCT04528667Phase 2
- Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19CompletedNCT04486001Phase 1
- Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19WithdrawnNCT04454398Phase 1